President Barack Obama this morning unveiled the Precision Medicine Initiative, it will include in its budget request for 2016 a hearing White House East Room packed with federal leaders of science, university researchers, patient advocacy groups and research, the guests of the Congress, and executives from the pharmaceutical industry. Basically, they seemed to rejoice in his plan to find ways to use genomics and other molecular information to tailor patient care.
After mocking his own knowledge of science a model of chromosomes made from pink swim noodles "was helpful for me," he said, Obama explained that accuracy of medicine ". deliver the right treatments at the right time, every time to the right person "such an approach" gives us one of the greatest opportunities for medical new breakthroughs we have ever seen, "he added. He then described the $ 215 million initiative, which includes new support for cancer genomics and molecular targeted drug testing at the National cancer Institute (NCI), and plan to study the links between genes, health and the environment as 1 million Americans pooling of existing participants in cohort studies.
"so, if we have a large data set, a large pool of people is varied, and that allows us to really draw not only the genome of a single person, but now we can begin to see connections and patterns and correlations that helps us refine exactly what we try to do regarding treatment , "the president said in his 20-minute speech, flanked by a red and blue model of the DNA double helix
in the room were different patients, Elana Simon, a young survivor of a rare liver cancer who helped sequence the type of cancer, who introduced the president. the former dominant basketball great Kareem Abdul-Jabbar, who apparently takes a targeted treatment for his leukemia; and cystic fibrosis patient William Elder, a medical student 27 years and invited to the State of the Union address that takes a new drug for the genetic flaw underlying form of the disease.
Representative Diana DeGette (D-CO), who worked on the 21st century Cures, a plan to accelerate the development of drugs and Senator Lamar Alexander (R-TN), which has similar goals were also present.
Sitting in the ranking were the two lieutenants who will carry the bulk of precision medicine plan: National Institutes of Health (NIH) Director Francis Collins and NCI Director Harold Varmus. Another participant was Craig Venter, who led the private effort to sequence the human genome in the 190s who were involved with public effort led by Collins. (There are fifteen, Venter was sitting in the same room with Collins when President Bill Clinton announced the first draft of the human genome.) Venter is now CEO of a company called Human Longevity Inc. that aims to sequence genomes of 1 million participants by 2020 a new competitor to private Collins federal cohort study, perhaps.
many other medical biobank genome projects in the centers and university health companies claim to be part of the cohort study of 1 million people. NIH will begin to explore which studies to include a meeting of 11 to 12 February (agenda here) which will also examine issues ranging from the protection of data using electronic medical records.
Amidst all the hoopla, a leading human geneticist in the audience offered a cautionary note. David Altshuler, who recently left the Vertex Pharmaceuticals Broad Institute in Boston, which makes drugs for cystic fibrosis brother, warns that even if the new American cohort study 1 million can discover new potential drug targets, will be 10 to 15 years before these discoveries lead to a successful drug.
"This is the first step," said Altshuler. "No amount of genome sequencing could never lead to a new drug directly."
Click here to see all of our coverage of the 2016 budget
Fixed, February 2 10:30 :. An earlier version of this story badly told that the treatment Elana Simon involved sequencing the tumor
0 Komentar